Package 'SurrogateSeq'

August 30, 2023

Title Assessing Heterogeneity in Surrogacy Using Censored Data

Type Package

Version 1.0 **Date** 2023-08-30

Author Layla Parast, Jay Bartroff

Description			
Provides functions to implement group sequential procedures that allow for early stopping to declare efficacy using a surrogate marker and the possibility of futility stopping. More details will be available in the future in: Parast, L. and Bartroff, J (2023+) ``A Group Sequential Procedure for Treatment Effect Testing Using a Surrogate Marker". License GPL Imports stats NeedsCompilation no Depends R (>= 3.5.0)			
		R topics documented	d:
		example.data pred.smooth.2 StudyA.aids	
		Index	
		delta.e.estimate	Tests for a treatment effect on the primary outcome using surrogate marker information
Description			
tion. This test borrows inf	reatment effect on the primary outcome using surrogate marker information from a prior study about the relationship between the surrogate to test for a treatment effect in the current study.		

2 delta.e.estimate

Usage

```
delta.e.estimate(sone = NULL, szero = NULL, szerop, yzerop, extrapolate = TRUE, mat = NULL, n1 = NULL, n0 = NULL)
```

Arguments

sone surrogate marker in the treated group in Study B
szero surrogate marker in the control group in Study B
szerop surrogate marker in the control group in Study A
yzerop primary outcome in the control group in Study A
extrapolate TRUE or FALSE; extrapolate for values outside of the support in Study A
mat for Study B, the user can either provide sone and szero or can provide a vector, mat, where the first n1 values are the surrogate marker in the treated group in the Study B, and the remaining values are the surrogate marker in the control group in Study B

n1 sample size of treated group in Study B; only needed if mat is provided instead

of sone and szero

no sample size of control group in Study B; only needed if mat is provided instead

of sone and szero

Value

delta.e estimated treatment effect using surrogate marker information

sd.e estimated standard error of treatment effect estimate

test.statistic.e

test statistic for treatment effect

p.value.e p-value for test statistic

delta.e.z test statistic

delta.e.p p-value of test statistic

Author(s)

Layla Parast

References

Parast, Cai, and Tian (2022+). Using a Surrogate with Heterogeneous Utility to Test for a Treatment Effect.

Examples

```
data(example.data)
delta.e.estimate(sone = example.data$s1, szero = example.data$s0, szerop = example.data$s0.p,
yzerop = example.data$y0.p)

data(StudyA.aids)
data(StudyB.aids)
s1.studyb = StudyB.aids$s1
s0.studyb = StudyB.aids$s0
s0.studya = StudyA.aids$s0
```

example.data 3

```
#24 weeks
```

```
delta.e.vec = delta.e.estimate(sone=s1.studyb$CD4_24weeks[!is.na(s1.studyb$CD4_24weeks)],
szero=s0.studyb$CD4_24weeks[!is.na(s0.studyb$CD4_24weeks)], szerop = s0.studya$CD4_24weeks,
yzerop = StudyA.aids$y0, extrapolate = TRUE)
delta.e.vec
```

example.data

Example data

Description

Example data

Usage

```
data("example.data")
```

Format

A list with 9 elements:

```
w0.p the baseline covariate in the control group in the prior study (Study A)
```

s0.p the surrogate marker in the control group in the prior study (Study A

 $y\emptyset.p$ the primary outcome in the control group in the prior study (Study A

w1 a baseline covariate in the treatment group in the current study (Study B)

wo a baseline covariate in the control group in the current study (Study B)

s1 the surrogate marker in the treatment group in the current study (Study B)

s0 the surrogate marker in the control group in the current study (Study B)

y1 the primary outcome in the treatment group in the current study (Study B)

yo the primary outcome in the control group in the current study (Study B)

Examples

```
data(example.data)
names(example.data)
```

4 StudyA.aids

pred.smooth.2

Calculates the conditional mean function

Description

Helper function; calculates the condition mean of Y given S, based on Study A data

Usage

```
pred.smooth.2(kernel.use,kernel.apply, bw,outcome)
```

Arguments

kernel.use surrogate values in the control group in Study A

kernel.apply surrogate values in Study B

bw bandwidth

outcome in the control group in Study A

Value

expected outcome for each surrogate value

Author(s)

Layla Parast

StudyA.aids

ACTG 320 clinical trial data

Description

Primary outcome and surrogate marker measurements over time from the ACTG 320 clinical trial data

Usage

```
data("StudyA.aids")
```

Format

A list with 4 elements:

- y1 the primary outcome in the treatment group in Study A; the primary outcome is defined as -1 times (log of RNA at 40 weeks log of RNA at baseline) because a DECREASE in RNA is better
- y0 the primary outcome in the control group in Study A
- s1 a dataframe of the surrogate markers at different time points in the treatment group in Study A; the surrogate marker is change in CD4 cell count from baseline to 4 weeks (CD4_4weeks), 8 weeks (CD4_8weeks), 24 weeks (CD4_24weeks), and 40 weeks (CD4_40weeks). Note that higher values indicate increasing CD4 cell count which is "better".
- so a dataframe of the surrogate markers at different time points in the control group in Study A

StudyB.aids 5

Examples

data(StudyA.aids)

StudyB.aids

ACTG 193A clinical trial data

Description

Surrogate marker measurements over time from the ACTG 193A clinical trial data. Note that the time points do not exactly match up to ACTG 320. In the paper, we use Study A surrogate data at 24 weeks to construct the conditional mean function applied to Study B at 16 weeks. Also note that some subjects are missing values of the surrogate at one or more time points. The naive estimate of the treatment effect using the surrogates uses all non-missing data available at each time point.

Usage

```
data("StudyB.aids")
```

Format

A list with 2 elements:

- s1 a dataframe of the surrogate markers at different time points in the treatment group in Study B; the surrogate marker is change in CD4 cell count from baseline to 8 weeks (CD4_8weeks), 16 weeks (CD4_16weeks), 24 weeks (CD4_24weeks), and 40 weeks (CD4_40weeks). Note that higher values indicate increasing CD4 cell count which is "better".
- so a dataframe of the surrogate markers at different time points in the control group in Study B

Examples

data(StudyB.aids)

Index